Dare Bioscience Updates on Multiple Pipeline Assets, Including Commercial Launch of Sildenafil Cream and Positive Ovaprene Phase 3 Interim Data
DARE sits 22% above its 52-week low of $1.61 on light trading volume (0.2× avg).
Summary
Dare Bioscience announced significant progress across its product pipeline, including the commercial launch of DARE to PLAY Sildenafil Cream, positive interim Phase 3 data for Ovaprene, and non-dilutive funding for DARE-HPV.
Key Events · Product Development and Regulatory · DARE
-
DARE to PLAY Sildenafil Cream Commercial Launch
DARE to PLAY Sildenafil Cream is now available for pre-order by prescription in select states as a compounded drug through a 503B-registered outsourcing facility partner. The company continues to pursue FDA's 505(b)(2) pathway for marketing approval.
-
Positive Ovaprene Phase 3 Interim Data
The investigational hormone-free monthly intravaginal contraceptive, Ovaprene, reported positive interim data and a Data Safety Monitoring Board (DSMB) recommendation in Q3 2025 for its Phase 3 pivotal study, which is currently enrolling and expected to complete enrollment in 2026.
-
Non-Dilutive Funding for DARE-HPV
The DARE-HPV program, an investigational antiviral vaginal insert for HPV-related cervical diseases, has received up to $10 million in non-dilutive funding, with $4.5 million received to date, to support its U.S. IND filing and progression to Phase 2 clinical development.
-
Near-Term Commercial Catalysts
The company anticipates the launch of DARE to RESTORE vaginal probiotics in Q1 2026 and the 503B launch of DARE to RECLAIM estradiol + progesterone intravaginal ring in early 2027, alongside nationwide availability of DARE to PLAY Sildenafil Cream in early 2026.
Analysis · DARE · Life Sciences
Dare Bioscience, a micro-cap company focused on women's health, provided a comprehensive update on its pipeline and commercialization strategy. The immediate availability of DARE to PLAY Sildenafil Cream for pre-order, even through a compounded drug pathway, represents a significant step towards revenue generation. The positive interim data and DSMB recommendation for the Ovaprene Phase 3 study are crucial for advancing its lead contraceptive candidate. Additionally, the non-dilutive funding for DARE-HPV and the outlined timelines for other product launches provide a clear roadmap for future catalysts, which is highly material for a company of this size.
At the time of this filing, DARE was trading at $1.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.4M. The 52-week trading range was $1.61 to $9.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.